Results 31 to 40 of about 2,182,415 (399)

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
French, N, Gilks, CF, Gordon, SB, Longwe, H, Molyneux, ME, Mwafulirwa, G, Mwaiponya, M, Mwalukomo, T, White, SA, Zijlstra, EE   +9 more
core   +4 more sources

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.
Stephen J. Thomas, E. Moreira, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, F. Polack, C. Zerbini, R. Bailey, K. Swanson, Xia Xu, Satrajit Roychoudhury, K. Koury, S. Bouguermouh, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Qi Yang, P. Liberator, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, W. Gruber, K. Jansen   +31 more
semanticscholar   +1 more source

Global economic burden per episode for multiple diseases caused by group A Streptococcus

npj Vaccines, 2023
Considering the lack of existing evidence on economic burden for diseases caused by group A Streptococcus, we estimated the economic burden per episode for selected diseases.
Jung-Seok Lee, Sol Kim, Jean-Louis Excler, Jerome H. Kim, Vittal Mogasale   +4 more
doaj   +1 more source

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021
Background Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 ...
S. Madhi, V. Baillie, C. Cutland, M. Voysey, A. Koen, L. Fairlie, S. Padayachee, K. Dheda, S. Barnabas, Q. Bhorat, Carmen Briner, G. Kwatra, K. Ahmed, P. Aley, Sutika Bhikha, J. Bhiman, A. Bhorat, J. du Plessis, A. Esmail, M. Groenewald, E. Horne, Shi-Hsia Hwa, A. Jose, T. Lambe, M. Laubscher, M. Malahleha, Masebole Masenya, Mduduzi S. L. Masilela, Shakeel Mckenzie, Kgaogelo Molapo, A. Moultrie, S. Oelofse, Faeezah Patel, S. Pillay, S. Rhead, H. Rodel, Lindie Rossouw, Carol Taoushanis, H. Tegally, Asha Thombrayil, Samuel van Eck, C. K. Wibmer, N. Durham, E. Kelly, T. Villafana, S. Gilbert, A. Pollard, Túlio de Oliveira, P. Moore, A. Sigal, A. Izu   +50 more
semanticscholar   +1 more source

Ability of vaccine strain induced antibodies to neutralize field isolates of caliciviruses from Swedish cats [PDF]

, 2015
Background: Feline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide. Its characteristically high mutation rate leads to escape from the humoral immune response induced by natural infection and/or vaccination and ...
Berndtsson, Louise Treiberg, Hosie, Margaret, Lindhe, Anna, Samman, Ayman, Thibault, Jean-Christophe, Wensman, Jonas Johansson   +5 more
core   +2 more sources

Effect of maternal separation and transportation stress on the bovine upper respiratory tract microbiome and the immune response to resident opportunistic pathogens

Animal Microbiome, 2021
Background The bovine upper respiratory tract (URT) microbiome includes opportunistic pathogens that cause respiratory disease and stress associated with maternal separation and transportation contributes to the severity of this respiratory disease ...
Nilusha Malmuthuge, Angela Howell, Natasa Arsic, Tracy Prysliak, Jose Perez-Casal, Philip Griebel   +5 more
doaj   +1 more source

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

New England Journal of Medicine, 2021
Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J. Sadoff, Mathieu le Gars, Georgi Shukarev, Dirk Heerwegh, C. Truyers, A. M. de Groot, Jeroen N. Stoop, Sarah M. Tete, W. Van Damme, I. Leroux-Roels, Pieter-Jan Berghmans, M. Kimmel, P. van Damme, J. D. de Hoon, William Smith, K. Stephenson, S. D. De Rosa, Kristen W. Cohen, M. McElrath, E. Cormier, Gert Scheper, D. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. van Hoof, H. Schuitemaker   +26 more
semanticscholar   +1 more source

Vaccine hesitancy: the next challenge in the fight against COVID-19

European Journal of Epidemiology, 2020
Vaccine hesitancy remains a barrier to full population inoculation against highly infectious diseases. Coincident with the rapid developments of COVID-19 vaccines globally, concerns about the safety of such a vaccine could contribute to vaccine hesitancy.
A. Dror, N. Eisenbach, S. Taiber, N. Morozov, Matti Mizrachi, Asaf Zigron, S. Srouji, E. Sela   +7 more
semanticscholar   +1 more source

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves [PDF]

, 2015
peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by
A Menanteau-Horta, A Vila, AR Peters, B Morein, B Morein, Bernadette Earley, BJF Bradshaw, BM Adair, Bryan Markey, C Pilette, CA Siegrist, CX Song, DG Bryson, DP Greenberg, EM Liebler-Tenorio, F Alexis, F Mansoor, Fawad Mansoor, FM Buonaguro, HM Chen, I Vangeel, J Phillips, J Pollock, JE Crowe, Joseph P. Cassidy, JS Salt, K Tahara, KJ Wiechelman, M Garinot, M Higaki, Michael D. Welsh, ML Hans, MS Lee, OV Kavanagh, PE Shewen, PK Smith, PR Wood, RE Brown, RM Zinkernagel, S Lofthouse, Simon Doherty, TG Kimman, YJ Kwon   +42 more
core   +1 more source

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

New England Journal of Medicine, 2021
Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least ...
Y. Bar-On, Y. Goldberg, Michael I. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. alroy-Preis, N. Ash, R. Milo, A. Huppert   +10 more
semanticscholar   +1 more source